EGFR and non-small cell lung carcinoma: Our in vitro study supported the findings from in silico molecular docking studies, which demonstrate that CRE compounds, especially caulersin (C2), have significant potential as anticancer agents for NSCLC, particularly in targeting proteins involved in EGFR Tyrosine Kinase Inhibitor Resistance pathways.